Targeting IL-6 by engineered Lactococcus lactis via surface-displayed affibody

• Post by: Ana Mitrović
• 20.August, 2022
• Comments off

Members of the Department Abida Zahirović and Aleš Berlec have recently published a paper entitled »Targeting IL-6 by engineered Lactococcus lactis via surface-displayed affibody« in Microbial Cell Factories (IF = 6.35). They developed lactic acid bacteria Lactococcus lactis with potent and selective IL-6 binding activity by displaying IL-6-specific affibody on its surface. Engineered bacteria were able to remove high amounts of IL-6 released from immune cells involved in the pathology of chronic inflammatory bowel disease. The developed strain is suitable for further development as an alternative treatment of inflammatory bowel disease, which combines local neutralization of IL-6 with the beneficial effects of oral probiotics. The paper can be accessed
at https://microbialcellfactories.biomedcentral.com/articles/10.1186/s12934-022-01873-7.